91 completed, 32 recruiting, 20 terminated, 15 unknown. 74 Phase 1, 69 Phase 2, 19 Not applicable, 9 Phase 3, 3 Early Phase 1.
Follow Hematologic Malignancies: new trials by email Literature Review of Hematologic Malignancies trials Research Report on Hematologic Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aberrant Expression of CD56 in Patients With Hematologic Malignancies. CD56 - Hematologic Malignancies | Recruiting | Asmaa Hassan mohamed Abdel Mawjoud | 38 | 2027-03-20 | 2026-03-18 | |
| Effects of Resistance Training on Recovery During Hematopoietic Stem Cell Transplantation 8-week Elastic Band Resistance Training Program - Hematologic Malignancies, Hematopoietic Stem Cell Transplantation | Not applicable | Not yet recruiting | Taipei Veterans General Hospital, Taiwan | 86 | 2026-10-12 | 2026-10-14 |
| A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine) - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 60 | 2026-10-09 | 2026-10-08 |
| Cognitive Impairment in Older Adults With Hematologic Malignancies Cognitive Impairment, Hematologic Malignancies | Not yet recruiting | Assiut University | 120 | 2026-09-26 | 2026-09-28 | |
| Rutgers University Study of the Genetics of Blood Cancers Blood Cancers, Blood Cancer | Recruiting | Rutgers, The State University of New Jersey | 10000 | 2026-09-22 | 2026-10-01 | |
| Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting Bleeding in Patients With Malignant Haematological Disorders and Severe Thrombocytopenia Additional blood sample - Thrombocytopenia, Platelet Transfusion | Recruiting | Centre Hospitalier Annecy Genevois | 410 | 2026-09-18 | 2026-10-22 | |
| Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer Cancer, Solid Tumor Cancer | Recruiting | Tempus AI | 1000 | 2026-08-01 | 2026-08-10 | |
| Early Discontinuation of Antibiotics in Paediatric High-risk Febrile Neutropenia Early Discontinuation of Antibiotics, Standard Antibiotic Continuation Strategy - Febrile Neutropenia (FN), Pediatric Cancer | Phase 4 | Not yet recruiting | Hospital Universitari Vall d'Hebron Research Institute | 136 | 2026-06-01 | 2026-05-15 |
| A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies BL-M24D1 - Multiple Myeloma, Hematologic Malignancies | Phase 1 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 33 | 2026-03-25 | 2026-06-04 |
| Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention Cyclophosphamide (primary intervention for GVHD prophylaxis) - Graft-versus-Host Disease (GVHD), Hematologic Malignancies | Phase 2 | Recruiting | Milton S. Hershey Medical Center | 41 | 2026-03-09 | 2026-04-03 |
| Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells - Hematologic Malignancies | Not applicable | Recruiting | University of Wisconsin, Madison | 38 | 2026-02-26 | 2026-09-14 |
| The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation Thiotepa, Fludarabine, G-CSF - Hematologic Malignancies | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 44 | 2026-02-20 | 2026-03-02 |
| A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant Cyclophosphamide, Mycophenolate Mofetil, Ruxolitinib - Hematologic Malignancies | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2026-01-20 | 2026-07-07 |
| Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy Educational Intervention, Health Telemonitoring, Questionnaire Administration - Hematologic Malignancies | Phase 3 | Recruiting | City of Hope Medical Center | 380 | 2026-01-14 | 2026-08-28 |
| A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies INCA036873 - Solid Tumors, Hematologic Malignancies | Phase 1 | Recruiting | Incyte Corporation | 280 | 2026-01-08 | 2026-10-09 |
| A Clinical Study of Allogenic CD19-CAR-T in the Treatment of R/R B-Cell Hematologic Malignancies 19UCART injection - Hematologic Malignancies, Lymphoma | Phase 1 | Not yet recruiting | YANRU WANG | 12 | 2025-12-22 | 2026-01-05 |
| Murottal as Adjunctive Intervention in Pediatric Murottal Intervention - Pediatric Cancer, Hematologic Malignancies | Not applicable | Completed | Universitas Airlangga | 20 | 2025-12-19 | 2026-10-09 |
| Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL), Fludarabine, Cyclophosphamide - Hematologic Malignancies, Hematologic Neoplasms | Phase 1 | Recruiting | National Cancer Institute (NCI) | 155 | 2025-11-14 | 2026-10-16 |
| A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy Anti-human CD7 CAR-NK cell injection - Immunology, Hematologic Malignancies | Early Phase 1 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 18 | 2025-09-01 | 2025-08-12 |
| PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) PUL-042, Placebo - Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT) | Phase 2 | Recruiting | Pulmotect, Inc. | 100 | 2025-06-27 | 2026-08-04 |
Showing 20 of 184. Sign in to see all of them.
Hematologic Neoplasms (184) · Myelodysplastic Syndromes (21) · Leukemia, Myeloid, Acute (19) · Lymphoma (19) · Leukemia (18) · Lymphoma, Non-Hodgkin (18) · Hodgkin Disease (17) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (16) · Multiple Myeloma (16) · Neoplasms (16) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (16) · Graft vs Host Disease (15) · Leukemia, Lymphocytic, Chronic, B-Cell (15) · Recurrence (8) · Hematologic Diseases (7)
Hemic and Lymphatic Diseases (184) · Neoplasms by Site (184) · Hematologic Diseases (177) · Neoplasms (168) · Immune System Diseases (64) · Neoplasms by Histologic Type (57) · Immunoproliferative Disorders (48) · Lymphoproliferative Disorders (48) · Lymphatic Diseases (45) · Pathological Conditions, Signs and Symptoms (34) · Bone Marrow Diseases (33) · Pathologic Processes (31) · Disease Attributes (28) · Leukemia (26) · Leukemia, Lymphoid (25)
fludarabine (22) · Tacrolimus (16) · Cyclophosphamide (14) · Whole-Body Irradiation (11) · Mycophenolic Acid (10) · fludarabine phosphate (10) · Melphalan (9) · Busulfan (8) · Thiotepa (7) · Granulocyte Colony-Stimulating Factor (6) · Rituximab (6) · Sirolimus (6) · Antilymphocyte Serum (5) · Methotrexate (5) · Stem Cell Transplantation (5)
M.D. Anderson Cancer Center (7) · National Cancer Institute (NCI) (6) · Dana-Farber Cancer Institute (5) · Amgen (4) · Fate Therapeutics (4) · Merck Sharp & Dohme LLC (4) · UNC Lineberger Comprehensive Cancer Center (4) · University of California, San Francisco (4) · Dartmouth-Hitchcock Medical Center (3) · Emory University (3) · Incyte Corporation (3) · Masonic Cancer Center, University of Minnesota (3) · Memorial Sloan Kettering Cancer Center (3) · Millennium Pharmaceuticals, Inc. (3) · Pfizer (3)
United States (131) · Italy (16) · France (15) · China (13) · Spain (12) · Canada (9) · Australia (8) · Germany (8) · South Korea (8) · United Kingdom (8) · Turkey (Türkiye) (6) · Hungary (5) · Netherlands (5) · Belgium (4) · Denmark (4)
Janel Long-Boyle, PharmD, PhD (2) · Janel R Long-Boyle, PharmD, PhD (2) · Kuang-Yueh Chiang, M.D. (2) · Natalie Grover, MD (2) · Neal Flomenberg, MD (2) · Nelson Chao, MD, MBA (2) · Patrick Stiff, MD (2) · Sherif Farag, MD, PhD (2) · William A Wood, MD (2)
PMID 10091805, PMID 10515382, PMID 10573044, PMID 12659416, PMID 15528753, PMID 15845896, PMID 16115130, PMID 16732175, PMID 16980990, PMID 17008536, PMID 17162214, PMID 17573453, PMID 17606446, PMID 18307672, PMID 18322708, PMID 18451242, PMID 18468541, PMID 18619375, PMID 18703664, PMID 18820709, PMID 19462317, PMID 19713456, PMID 19955306, PMID 20350611, PMID 20685246, PMID 20837781, PMID 20953908, PMID 21393326, PMID 21417678, PMID 21868572, PMID 22050904, PMID 22093814, PMID 22461866, PMID 22491731, PMID 22776268, PMID 22814329, PMID 23065508, PMID 23146063, PMID 23190221, PMID 23485478, PMID 23524640, PMID 23954992, PMID 23993427, PMID 23996087, PMID 24179471, PMID 24295572, PMID 25075128, PMID 25299140, PMID 25386344, PMID 25428504
2009 (2), 2017 (2), 2023 (2), 2025 (2), 2016 (1), K01TW009488 (1), K08CA273684 (1), P01CA015396 (1), P01CA065493 (1), R00HL088021 (1), R01CA276040 (1)